TABLE 1.

Main clinical features of 182 patients with epithelial ovarian cancer (EOC) with and without therapy‐related myeloid neoplasms (t‐MN) following poly(ADP‐ribose) polymerase inhibitors (PARPi) and previous poly‐chemotherapy

Characteristics	Patients without t‐MN (n = 166)	Patients with t‐MN (n = 16)
Median age at EOC diagnosis	54 (range 33‐78)	52 (range 39‐69)
Histology, n (%)
Serous carcinoma	144 (87%)	15 (94%)
Endometrioid carcinoma	7 (4%)	1 (6%)
Clear cell carcinoma	5 (3%)	0
Mixed carcinoma	5 (3%)	0
NOS carcinoma	5 (3%)	0
Grade, n (%)
High	156 (94%)	15 (94%)
Intermediate	4 (2%)	1 (6%)
Unknown	6 (4%)	0
FIGO stage, n (%)
I	7 (4.5%)	0
II	7 (4.5%)	2 (13%)
III	119 (71%)	13 (81%)
IV	33 (20%)	1 (6%)
Germline BRCA1/2 status, n (%)
Mutated	79 (47.5%)	9 (56%)
Wild type/VUS	68 (41%)	5 (31%)
Unknown a	19 (11.5%)	2 (13%)
Prior chemotherapy lines before PARPi, n (%)
1‐2	64 (38%)	8 (50%)
3‐4	64 (38%)	5 (31%)
≥5	38 (24%)	3 (19%)
Type of PARPi, n (%)
Olaparib b	100 (60%)	9 (56%)
Niraparib	63 (38%)	6 (38%)
Rucaparib b	4 (2%)	1 (6%)
PARPi therapy, n (%)
Treatment	56 (34%)	1 (6%)
Maintenance	111 (66%)	15 (94%)
Duration of PARPi therapy, n (%)
Median (months)	7.4 (range 0.8‐110.8)	18.5 (range 4.1‐42.2)
≤6 months	74 (45%)	3 (19%)
7‐17 months	55 (33%)	3 (19%)
≥18 months	37 (22%)	10 (62%)
Presents status, n (%)
Dead	54 (32%)	12 (75%)
Alive	94 (57%)	4 (25%)
Lost at follow‐up	18 (11%)	0

Abbreviations: BRCA, breast cancer gene; FIGO, International Federation of Gynecology and Obstetrics; NOS, not otherwise specified; VUS, variant of uncertain significance.

^a Patients were enrolled in a 2010 clinical trial that did not require assessment of the BRCA status.

^b A single patient received both olaparib and rucaparib as maintenance.